Particularly, a phase III trial (VIKTORIA-1, NCT05501886) is evaluating gedatolisib, an intravenously administered pan-PI3K/mTOR inhibitor [139], in combination with fulvestrant with or without palbociclib in advanced or metastatic HR+/HER2− breast cancer that is progressing on or after AI plus CDK4/6i. This evidence concerns the gene MTOR and breast cancer.